Cargando…
Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma
Constitutive activation of the chemokine receptor CXCR4 has been associated with tumor progression, invasion, and chemotherapy resistance in different cancer subtypes. Although the CXCR4 pathway has recently been suggested as an adverse prognostic marker in diffuse large B-cell lymphoma, its biologi...
Autores principales: | Recasens-Zorzo, Clara, Cardesa-Salzmann, Teresa, Petazzi, Paolo, Ros-Blanco, Laia, Esteve-Arenys, Anna, Clot, Guillem, Guerrero-Hernández, Martina, Rodríguez, Vanina, Soldini, Davide, Valera, Alexandra, Moros, Alexandra, Climent, Fina, González-Barca, Eva, Mercadal, Santiago, Arenillas, Leonor, Calvo, Xavier, Mate, José Luís, Gutiérrez-García, Gonzalo, Casanova, Isolda, Mangues, Ramón, Sanjuan-Pla, Alejandra, Bueno, Clara, Menéndez, Pablo, Martínez, Antonio, Colomer, Dolors, Tejedor, Roger Estrada, Teixidó, Jordi, Campo, Elias, López-Guillermo, Armando, Borrell, José Ignacio, Colomo, Luis, Pérez-Galán, Patricia, Roué, Gaël |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442946/ https://www.ncbi.nlm.nih.gov/pubmed/29954928 http://dx.doi.org/10.3324/haematol.2017.180505 |
Ejemplares similares
-
Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells
por: Body, Simon, et al.
Publicado: (2017) -
Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation
por: Dlouhy, Ivan, et al.
Publicado: (2021) -
Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation
por: Dlouhy, Ivan, et al.
Publicado: (2022) -
BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma
por: Esteve-Arenys, Anna, et al.
Publicado: (2018) -
Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma
por: Balsas, P., et al.
Publicado: (2017)